Last reviewed · How we verify
Small intestine cancer
Approved treatments
- Carac · Spectrum Pharms
- Eloxatin · Yakult Honsha
Oxaliplatin forms platinum-DNA crosslinks that inhibit replication and transcription. - Carac · Extrovis
- Fusilev · Spectrum Pharms
- Fusilev · Acrotech Biopharma
Fusilev works by bypassing the enzyme dihydrofolate reductase, allowing normal cell growth and DNA synthesis.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Small intestine cancer patent landscape — cliff calendar, originator estates, attackable patents
- Small intestine cancer treatment landscape brief
- Small intestine cancer treatment updates RSS
Frequently asked questions about Small intestine cancer
What drugs treat Small intestine cancer?
Tracked treatments include Carac, Eloxatin, Fusilev.
What is the treatment for Small intestine cancer?
Standard treatment for Small intestine cancer includes Carac, Eloxatin, Fusilev. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Small intestine cancer patent cliff · Small intestine cancer CI report
- Treatment: Carac · Spectrum Pharms
- Treatment: Eloxatin · Yakult Honsha
- Treatment: Carac · Extrovis
- Treatment: Fusilev · Spectrum Pharms
- Treatment: Fusilev · Acrotech Biopharma
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing